Blood Gas Analyzers
Archived on November 29, 2025. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 11:00 AM CST
- Posted
- November 7, 2025
- Notice type
- Sources Sought
- Set-aside
- Indian Economic Enterprise (IEE) Set-Aside (specific to Department of Interior and Indian Health Services)
- NAICS
- 334516: Analytical Laboratory Instrument Manufacturing
- Agency
- Department of Health and Human ServicesINDIAN HEALTH SERVICE
Notice details
- Office
- OK CITY AREA INDIAN HEALTH SVC
- Place of performance
- Oklahoma, 73507
- Last updated
- Nov 6, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- 246-26-Q0001
- Notice ID
- 08b75f4b5cec488fb22d02b1796878fb
Description
This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. Pursuant
to 48 CFR Part 326, Subpart 326.603-3 and IHM 5.5- 6, Indian Health Service must use the negotiation authority of
the Buy Indian Act, 25
U.S.C. 47, to give preference to Indian Economic Enterprises (IEE) whenever the use of that authority is authorized
and practicable.
The Government is seeking to identify Indian Small Business Economic Enterprises (ISBEEs) capable of performing
the below Indian Health Services (IHS) requirement. Any vendor responding to this notice should submit their
capability statement as well as the Buy Indian Act Indian Economic Enterprise Representation Form (attached).
Instructions for submission are outlined below.
Indian Small Business Economic Enterprises (ISBEEs) and other small business are highly encouraged to respond to
this notice. However, firms should understand that generic capability statements are not sufficient for effective
evaluation of their capacity and capability to perform the work required.
Responses must directly demonstrate the company’s capability, experience, and ability to provide a Combination
Ophthalmic Surgical Laser System.
The Government requests interested parties submit a written response to this notice, which includes:
1. Company Name.
2. Company Socioeconomic Status.
3. Company System for Award Management (SAM) Unique Entity Identifier (UEI) number.
4. Company point of contact, mailing address, and telephone number(s), and website address
Name, telephone number, and e-mail address of a company point of contact who has the authority and
knowledge to clarify responses with government representatives.
5.
6. DUNS Number:
7. Cage Code:
8. Tax ID
9. Date submitted.
10. Applicable company GSA Schedule number or other available procurement vehicle.
Company’s System for Award Management (SAM) registration status. All respondents must register on the
SAM located at http://www.sam.gov/.
11.
12. Submit Indian Health Service Buy Indian Act Indian Economic Enterprise Representation Form (attached)
Disclaimer and Important Notes. This notice does not obligate the Government to award contract. Any information
provided by industry to the Government as a result of this sources sought synopsis is strictly voluntary. Responses
will not be returned. No entitlements to payment of direct or indirect costs or charges to the Government will arise
as a result of contractor submission of responses, or the Government's use of such information or otherwise pay for
the information provided in response. The Government reserves the right to use information provided by
respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice
should ensure that its response is complete and sufficiently detailed to allow the Government to determine the
organization’s qualifications to perform the work.
Respondents are advised that the Government is under no obligation to acknowledge receipt of the information
received or provide feedback to respondents with respect to
any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may
be published on a government GPE. However, responses to this notice will not be considered adequate responses to
a solicitation.
Confidentiality. No proprietary, classified, confidential, or sensitive information should be included in your
response. The Government reserves the right to use any non- proprietary technical information in any resultant solicitation(s).
How to respond: Please include the notice IHS 246-25-Q-0090 Combination Ophthalmic Surgical Laser System in the
subject line. Responses must be submitted via email to the Contract Specialist, Audrey Yackeyonny at
audrey.yackeyonny@ihs.gov no later than 12:00 PM CST on August 22, 2025.
Capability statements will not be returned and will not be accepted after the due date. The maximum number of
pages for this submission is five (5) pages.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
Lifecycle
- 3Version 3Sources SoughtArchivedCurrent
Blood Gas Analyzers
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
The U.S. Army Corps of Engineers (USACE) requires a new handheld energy dispersive X-ray fluorescence (XRF) analyzer. The primary purpose of this instrument is to conduct immediate, on-site screening for lead (Pb) content in various materials, such as painted steel structures and coatings. This capability is essential for performing industrial hygiene assessments and environmental compliance inspections in accordance with federal and state lead screening requirements. | - | Solicitation | 09/07/2026 |
1. Disclaimer THIS IS A SOURCES SOUGHT NOTICE ONLY. This notice is issued solely for information and market research planning purposes. It does not constitute a Request for Quotation (RFQ), Request for Proposal (RFP), or Invitation for Bids (IFB), nor does it restrict the Government to a particular acquisition approach. No contract or purchase order will be awarded from this announcement, and the Government will not reimburse respondents for any costs incurred in preparing a response. 2. Background and Purpose The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions,, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Section of Cell Cycle Regulation, has a requirement for a Brand-Name Lonza 4D-Nucleofector® System consisting of the following: 4D-Nucleofector Core Unit, Part No. AAF-1003B – Quantity (1) EA 4D-Nucleofector X Unit, Part No. AAF-1003X - Quantity (1) EA 3. One-year warranty extension for each unit. Or a functional domestic equivalent, to support ongoing NIH-funded research involving the genetic manipulation of mammalian cells. Because NICHD's ongoing studies rely on previously validated electroporation pulse-code workflows, experimental protocols, and Nucleocuvette™ consumables established on a prior-generation Lonza Nucleofector platform, the Lonza 4D-Nucleofector® System is the primary known platform capable of ensuring experimental reproducibility and data continuity without requiring costly and time-consuming protocol re-optimization or re-validation. The Office of Acquisitions is conducting market research to identify qualified vendors—including small businesses, authorized distributors, and domestic manufacturers—and specifically seeks market information to determine: 1. Authorized Lonza Sources: The availability of Lonza Walkersville, Inc. or authorized distributors/resellers (including small businesses, HUBZone, 8(a), SDVOSB, WOSB, and Small Disadvantaged Businesses under NAICS 334516) capable of supplying new Lonza equipment with full manufacturer-backed warranties. 2. Buy American Act (FAR Part 25) Compliance: The availability of any domestic end products manufactured in the United States capable of meeting all functional, warranty, training, and legacy workflow-continuity requirements outlined in Section 3 without requiring experimental re-validation. 3. Technical Requirements and Salient Characteristics To meet the Government's minimum requirements, the proposed system must satisfy all functional and technical specifications from the Statement of Work alongside the laboratory's workflow-continuity constraints: Core Control Unit: The system shall include a Lonza 4D-Nucleofector® Core Unit (or a domestic equivalent central control unit) capable of controlling and operating advanced electroporation-based transfection protocols. Small-Volume Transfection Module: The system shall include a Lonza 4D-Nucleofector® X Unit (or a domestic equivalent functional module) capable of processing small-volume samples (specifically ranging from 20 µL to 100 µL) and supporting transfection of primary cells and other difficult-to-transfect cell types. Nucleic Acid & Reagent Delivery: The system shall support delivery of plasmid DNA, RNA, siRNA, CRISPR/Cas9 reagents, and other nucleic acid-based materials into mammalian cells. Optimized Transfection Performance: The system shall provide optimized electroporation programs designed to maximize transfection efficiency while maintaining high post-transfection cell viability. Sensitive Cell Applications: The system shall support research applications involving primary cells, stem cells, immune cells, and other sensitive cell populations that are not efficiently transfected using conventional lipid-based methods. Software and Protocols: The system shall include manufacturer-provided software and protocols necessary for operation of the instrument. Warranty Coverage: The system shall include a minimum one-year manufacturer warranty and one-year warranty extension coverage for both the Core Unit and X Unit (two years total coverage). Warranty coverage shall begin upon Government acceptance of the equipment and continue in accordance with the manufacturer's warranty terms. Consumable & Legacy Protocol Continuity: If proposing Lonza equipment, the system shall be 100% compatible with commercially available Lonza Nucleofector® reagents, Nucleocuvette™ consumables, and existing pulse-code workflows previously developed and validated on a prior-generation Lonza Nucleofector platform. If proposing a domestic alternative, the vendor must demonstrate that its system and consumables achieve equivalent transfection efficiency and post-transfection cell viability across NICHD's existing mammalian cell workflows without requiring protocol re-optimization or experimental re-validation. Delivery, Installation, and Training: Equipment must be delivered to NIH Bethesda (Building 49) and installed, with on-site or virtual user training for up to five (5) NIH personnel completed within 30 days of installation (covering system operation, software functionality, routine maintenance, and basic troubleshooting). All delivery, installation, and training shall be completed within the 12-month period of performance from award. 4. Capability Statement Submission Instructions Interested organizations that believe they can meet all requirements outlined in Section 3 are invited to submit a tailored Capability Statement (no more than 5 pages) containing the following information: 1. Company Profile: Organization name, mailing address, primary Point of Contact (name, title, email, and telephone number), SAM.gov Unique Entity ID (UEI), and CAGE code. 2. Business Size & Socioeconomic Status: Business size under NAICS 334516 (1,000-employee size standard) and applicable socioeconomic designations (e.g., Small Business, Woman-Owned, Veteran-Owned, Service-Disabled Veteran-Owned, HUBZone, 8(a)). 3. Contract Vehicles: Identification of any existing federal contract vehicles held by the vendor through which this equipment can be ordered (e.g., GSA Multiple Award Schedule), or confirmation of open-market availability. 4. Country of Origin (COO): Explicit identification of the manufacturing country of origin for all proposed hardware components and confirmation of whether the system qualifies as a domestic end product under the Buy American Act (FAR Part 25). 5. Technical Capability & Authorization: Product brochures, technical specifications, and catalog numbers demonstrating compliance with every requirement in Section 3. If proposing Lonza equipment: Documentation confirming status as an Authorized Distributor/Reseller eligible to provide new equipment and manufacturer-backed warranties. If proposing a domestic alternative: Technical evidence proving equivalent transfection performance and workflow continuity with existing NICHD mammalian cell protocols without requiring experimental re-validation. 6. Rough Order of Magnitude (ROM) Pricing (Optional): Non-binding budgetary pricing estimate for market research purposes. 5. Place of Performance: NIH, 9000 Rockville Pike, Bethesda, MD 20892 6. Submission Deadline and Contact Information Please submit electronic Capability Statements in PDF or Microsoft Word format via email to Tina Robinson at robinsti@mail.nih.gov no later than November 18, 2026, at 11:00 AM EST. Telephone inquiries will not be accepted. Capability Statements must reference Notice Number 75N98027R00019. Email submissions and any questions must be sent to robinsti@mail.nih.gov and include Notice Number 75N98027R00019 in the subject line. Capability Statements and attachments will not be returned to the sender. This synopsis is for information and planning purposes only and shall not be construed as a commitment by the Government, nor will the Government pay for information solicited. | - | Market Research | 11/18/2026 |
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Illumina, Inc. Acquisition Description: The purpose of this acquisition is to purchase two Illumina MiSeq i100 series instruments. These instruments will be used by the NIH HLA Laboratory to produce high resolution HLA typing results for the numerous transplant protocols supported by the laboratory. It will replace the current Illumina MiSeq instruments in the lab that were purchased in 2021 and 2022. The vendor will discontinue service on the current model of the MiSeq. New instruments are required to ensure time to validate these replacements before discontinuation of service. The total dollar value for this order is $139,100.52. The MiSeq is an integrated instrument that performs clonal amplification, genomic DNA sequencing, and data analysis with base calling, alignment, variant calling, and reporting in a single run. The MiSeq provides the Lab with the highest HLA typing results possible. The transplant protocols served by the HLA Lab require highest resolution possible to increase the chance of a successful transplant. The HLA Lab currently owns two MiSeq instruments, so the procedures and Quality Control assessments are in place. The order aims to replace the Illumina Miseq – s/n M07700 (property ID is 02223449) and s/n M08636 (property ID is 02268689) that were purchased in 2019 and 2022. Replacement is necessary to ensure proper performance of these instruments prior to discontinuation of service for the current model of the Illumina MiSeq instruments by the vendor. The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-OLAO-CC-27-000836) by 12:00 PM eastern standard time on 11/27/2026 to: valerie.gregorio@nih.gov. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. | - | Pre-Solicitation | 11/27/2026 |
(i)This is a combined synopsis/solicitation for commercial items prepared in accordancewith FAR Subpart 12.6, as supplemented with additional information included in thisnotice. This announcement constitutes the only solicitation; proposals are beingrequested, and a separate written solicitation will not be issued. (ii)The solicitation number is 75N98027Q00077. This solicitation is issued as a competitiveRequest for Quotation (RFQ) / combined synopsis/solicitation for commercial productsand commercial services using a Brand Name restriction in accordance with FAR 13.106-1(b)(1)(i). A Brand Name Justification is attached to this notice in accordance with FAR5.102(a)(6). This acquisition is conducted under the authority of FAR 12.603, StreamlinedSolicitation for Commercial Products or Commercial Services, in conjunction with FAR Part13 Simplified Acquisition Procedures, and is not expected to exceed the simplifiedacquisition threshold. The National Institutes of Health (NIH), Office of the Director, Officeof Acquisitions, seeks to award a Firm-Fixed-Price (FFP) Purchase Order to theresponsible offeror whose quotation represents the best value to the Government. (iii)The solicitation document and incorporated provisions and clauses are those in effectthrough Federal Acquisition Circular (FAC) number 2026-01 and effective date 03/13/2026. (iv)The associated NAICS code is 334516 (Analytical Laboratory InstrumentManufacturing), and the small business size standard is 1,000 employees. The ProductService Code (PSC) is 6640 (Laboratory Equipment and Supplies). [X]This requirement is set aside for Small Business concerns. | - | Combined Synopsis | 11/24/2026 |
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00072. This solicitation is issued as a competitive combined synopsis/solicitation for commercial products or commercial services restricted to the Brand Name specified herein in accordance with FAR 13.106-1(b)(1)(i). The Government intends to award a firm-fixed-price purchase order resulting from this solicitation using competition among the Original Equipment Manufacturer (OEM) and its authorized distributors. This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, on behalf of the National Heart, Lung, and Blood Institute (NHLBI), seeks to award a firm-fixed-price purchase order to the responsible offeror whose proposal represents the best value to the Government. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 334516 (Analytical Laboratory Instrument Manufacturing), and the small business size standard is 1,000 employees. ¿ This requirement is unrestricted. (v) Description of Requirement: The National Heart, Lung, and Blood Institute (NHLBI), Laboratory of Advanced Microscopy and Biophotonics (LAMB), requires one (1) Brand Name Spectra-Physics (Newport Corporation / MKS Instruments) InSight® X3¿ Dual Ultrafast Laser System to integrate with an existing Thorlabs Veneto inverted multiphoton microscope for Fluorescence Lifetime Imaging Microscopy (FLIM) and Stimulated Raman Scattering (SRS) pump-probe experiments studying the effects of chemotherapeutic agents on cellular metabolism. | - | Combined Synopsis | 11/20/2026 |
Additional Details
Solicitation Number
246-26-Q0001
Archive Date
Nov 29, 2025
Office Address
OKLAHOMA CITY, OK, 73114